Published in

Nature Research, Nature Communications, 1(11), 2020

DOI: 10.1038/s41467-020-17703-6

Links

Tools

Export citation

Search in Google Scholar

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Journal article published in 2020 by David Simon ORCID, Koray Tascilar ORCID, Gerhard Krönke, Arnd Kleyer ORCID, Mario M. Zaiss, Franz Heppt, Christine Meder, Raja Atreya, Entcho Klenske, Peter Dietrich, Abdullah Abdullah, Thorsten Kliem, Giulia Corte, Harriet Morf, Moritz Leppkes ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractImmune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.